A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Key Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

2. Confirmed diagnosis of symptomatic multiple myeloma (MM) by International MyelomaWorking Group (IMWG) diagnosis criteria

3. Measurable disease, according to the 2016 IMWG response criteria, as defined in theprotocol

4. No prior therapy for MM, with the exception of prior emergent or palliativeradiation and up to 1 month of single-agent corticosteroids, with washout periods asper the protocol

5. Participants must have evidence of adequate bone marrow reserves and hepatic, renaland cardiac function as defined in the protocol

6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiacfunction to be considered transplant-eligible. The specific thresholds for adequateorgan function are as per institutional guidance.

Key Exclusion Criteria:

1. Receiving any concurrent investigational agent with known or suspected activityagainst MM, or agents targeting the A proliferation-inducing ligand (APRIL)/Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis

2. Known central nervous system (CNS) involvement with MM, known or suspectedprogressive multifocal leukoencephalopathy (PML), a history of neurocognitiveconditions, or CNS movement disorder, or history of seizure within 12 months priorto study enrollment

3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure orhypercalcemia not responsive to standard medical interventions), in urgent need oftreatment with chemotherapy

4. Diagnosis of non-secretory MM, active plasma cell leukemia, primary light-chain (AL)amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or knownPOEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,endocrinopathy, monoclonal protein, and skin changes)

Note: Other protocol-defined Inclusion/Exclusion criteria apply